文献速递湿疹皮炎与荨麻疹

特应性皮炎系统免疫调节治疗的真实世界不良事件:TREAT NL登记研究

Real-world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: Results from the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-11-29

本研究基于TREAT NL登记,前瞻性多中心观察266例接受系统免疫调节治疗的特应性皮炎患者,收集422患者年安全性数据。129例(48.5%)报告224例(潜在)药物相关不良事件,部分事件发生率高于药品说明书,并发现度普利尤单抗相关新发不良事件。

要点

  • 真实世界登记可补充系统免疫调节治疗不良事件发生率信息。
  • 度普利尤单抗部分不良事件发生率高于说明书,包括嗜酸性粒细胞增多、睑缘炎等。
  • 口服甲氨蝶呤疲劳发生率高于说明书,需临床关注。

核心结论

  • 特应性皮炎患者登记中报告的不良事件可补充估计发生率并辅助临床决策。

研究设计与样本

  • 基于TREAT NL登记的前瞻性多中心观察性队列研究,纳入266例成人和儿童特应性皮炎患者。

主要发现

  • 共收集422患者年安全性数据,129例(48.5%)报告224例(潜在)药物相关不良事件。
  • 与度普利尤单抗说明书相比,嗜酸性粒细胞增多、睑缘炎、干眼和头颈部红斑发生率更高(报告≥5次)。
  • 口服甲氨蝶呤患者疲劳发生率高于说明书。
  • 度普利尤单抗患者发现两种新药相关不良事件(报告≥5次):非感染性结膜炎和睑板腺功能障碍。

临床怎么用

  • 临床应关注度普利尤单抗相关嗜酸性粒细胞增多、睑缘炎、干眼、头颈部红斑及非感染性结膜炎和睑板腺功能障碍。
  • 口服甲氨蝶呤治疗时需监测疲劳症状。

局限性

  • 真实世界登记数据可能存在报告偏倚,且原文未报告具体发生率数值和统计比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence on the (long-term) safety of systemic immunomodulating therapies in atopic dermatitis (AD) generated by real-world data is sparse. OBJECTIVES: To describe real-world reported adverse drug reactions (AEs) related to systemic immunomodulating therapy in patients with AD and to compare the incidence rates of AEs with the Summaries of Product Characteristics (SmPCs). METHODS: We conducted an observational prospective multi-centre cohort study, using the TREAT NL registry. All severe AEs, AEs of special interest and serious AEs in adult and paediatric patients on systemic immunomodulating treatment (ciclosporin, methotrexate, azathioprine, mycophenolic acid, dupilumab, tralokinumab, baricitinib and upadacitinib) were assessed. Incidences rates of all (potentially) drug-related AEs were standardized in patient years and compared to the cumulative incidences in the associated SmPCs. RESULTS: We collected 422 patient years of safety data from 266 patients, of whom 129 (48.5%) reported a total of 224 (potentially) drug-related AEs. Compared to dupilumab's SmPC, higher incidence rates were found for four AEs (reported ≥5 times): eosinophilia, blepharitis, dry eyes and head and neck erythema (i.e. dupilumab facial redness). A higher incidence rate of fatigue was found in patients on oral methotrexate in our cohort compared to the SmPC. Two new drug-related AEs (reported ≥5 times) were found in patients on dupilumab, including non-infectious conjunctivitis and meibomian gland dysfunction. CONCLUSIONS: Real-world reported AEs captured in AD patient registries can add information on the estimated incidence of AEs and benefit clinical decision aids. Future studies using data derived from the TREAT NL registry combined with data from other registries within the TREAT Registry Taskforce will provide more information on (rare) AEs associated with immunomodulating therapy in AD patients.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Musters AH, van Lookeren FL, van der Gang LF, et al. Real-world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: Results from the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. J Eur Acad Dermatol Venereol. 2023. PMID: 38031478. doi:10.1111/jdv.19643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。